The “one face to the customer” approach in customs would allow speeding up exports by Ukrainian pharmaceutical manufacturers, Commercial Director of PJSC Research and Industrial Center Borschahivka chemical and pharmaceutical plant Yevhen Sova has said. “The “one face to the customer” approach is intended to significantly facilitate the customs clearing and declaration of goods. We, for our part, are actively expanding and developing exports. The plant’s products are presented in 19 countries, and the share of exports is over 12%. We understand all benefits that the initiative could bring. In particular, this would allow supplying medicines more quickly and with smaller expenses,” he told Interfax-Ukraine.
At the same time, commenting on the completion of the transition period for the introduction of the updated order of information exchange at the Ukrainian customs using the “one face to the customer” approach, Sova said that “as for any innovation at the state level, it takes time to tune the work, identify and eliminate possible inconsistencies.” “This is a natural process,” he said.
At the same time Sova said that the state should ensure the competent implementation of the “one face to the customer” approach and also provide for clear rules and instructions that will allow fully implementing the changes, monitor the quality of their implementation and guarantee the expected result, namely, to simplify the mechanism of entering foreign markets for Ukrainian products.
It will be necessary to create infrastructure for vaccine production in Ukraine from scratch, while the state support program could contribute to this, Commercial Director of PJSC Borschahivsky Chemical and Pharmaceutical Plant Yevhen Sova believes. “Today it will be necessary to create infrastructure for vaccine production in Ukraine virtually from scratch. This is quite a long process, because we are talking about the construction of new workshops, the launch of additional production lines, passage of audits and confirmation of quality according to the standards,” he told Interfax-Ukraine.
At the same time, the expert noted that “Ukrainian pharmaceutical manufacturers can implement this.” “The technical equipment of domestic companies as a whole allows building new necessary infrastructure, paying special attention to the sites of quality control,” he said.
According to the expert, the state support program can become an impetus for domestic pharmaceutical producers and a signal for starting work on the organization of such production. “Such a program will contribute to the process as much as possible. It can include public-private partnership, tax-exempt status, simplified inspection procedures and other options, including subsidies,” he said.